Group 1 - The core viewpoint of the article highlights the successful publication of clinical trial results for the combination therapy of KRAS G12C inhibitor glecirasib and SHP2 inhibitor JAB-3312 in a leading medical journal, marking a significant milestone in cancer treatment [1] - The open-label Phase I/IIa clinical study conducted in China included 171 patients with KRAS G12C mutated non-small cell lung cancer (NSCLC), demonstrating a 71% objective response rate (ORR) and a median progression-free survival (mPFS) of 12.2 months in treatment-naive patients [1] - This combination therapy shows a competitive edge over the current standard treatment of immunotherapy plus chemotherapy, indicating its potential as a leading first-line treatment option [1] Group 2 - Currently, the KRAS G12C and SHP2 inhibitors are undergoing Phase III clinical trials in China, which will directly compare this combination therapy with existing standard treatment pathways [2] - The aim is to position this dual oral therapy as the first SHP2 combination treatment likely to receive global approval [2]

Core Insights - The company, Goss, announced the publication of clinical I/IIa study results for its KRAS G12C inhibitor, Glecirasib, in combination with SHP2 inhibitor, JAB-3312, in the prestigious medical journal, The Lancet Respiratory Medicine, marking the first systematic clinical data for this dual oral therapy to be featured in such a high-impact publication [1] Group 1 - The open-label clinical I/IIa study was conducted in China, enrolling 171 patients with KRAS G12C mutated non-small cell lung cancer (NSCLC), including 102 treatment-naive patients [1] - The combination therapy achieved a 71% objective response rate (ORR) and a median progression-free survival (mPFS) of 12.2 months in first-line patients, demonstrating a leading standard in KRAS G12C related first-line treatment [1] - Compared to the current standard treatment of immunotherapy plus chemotherapy, this chemotherapy alternative shows a highly competitive profile [1] Group 2 - Currently, KRAS G12C inhibitors and SHP2 inhibitors are undergoing phase III clinical trials in China, directly comparing this combination therapy with existing standard treatment pathways in first-line patients [2] - This dual oral combination is positioned to potentially become the first SHP2 combination therapy to receive global approval [2]